As filed with the Securities and Exchange Commission on June 27, 2019
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
VASCULAR BIOGENICS LTD.
(Exact Name of Registrant as Specified in its Charter)
| Israel | | Not applicable |
(State or Other Jurisdiction of
Incorporation or Organization) | | (I.R.S. Employer
Identification No.) |
8 HaSatat St.
Modi’in
Israel 7178106
972-634-6450
(Address of Principal Executive Offices)
Employee Share Ownership and Option Plan (2014)
(Full Title of the Plans)
Puglisi & Associates
850 Library Avenue
Suite 204
Newark, Delaware 19711
(302) 738-6680
(Name and Address of Agent For Service)
Copies to:
| Mitchell S. Bloom, Esq. | | Yuval Horn, Adv. |
| Lawrence S. Wittenberg, Esq. | | Keren Kanir, Adv. |
| Goodwin Procter LLP | | Horn & Co., Law Offices |
| 100 Northern Ave | | Amot Investments Tower |
| Boston, MA 02210 | | 2 Weizmann St., 24th Floor |
| (617) 570-1055 | | Tel Aviv, Israel 6423902 |
| | | 972-3-637-8200 |
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
| Large accelerated filer | [ ] | Accelerated filer | [X] |
| | | | |
| Non-accelerated filer | [ ] | Smaller reporting company | [ ] |
| | | | |
| | | Emerging growth company | [X] |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act [X]
CALCULATION OF REGISTRATION FEE
Title of Securities
to be Registered | | | Amount
to be
Registered (1) | | | Proposed
Maximum
Offering Price
per Share (2) | | | Proposed
Maximum
Aggregate
Offering
Price | | | Amount of
Registration
Fee | |
| Ordinary Shares, NIS 0.01 par value per share | | | 1,765,474 | (3) | | $ | 1.19 | | | $ | 2,100,914.60 | | | $ | 255 | |
| 1) | Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional ordinary shares which become issuable under the 2014 Employee Share Ownership and Option Plan (the “2014 Plan”) by reason of any share dividend, share split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding ordinary shares. |
| | |
| 2) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on the average of the high and low sale prices of the Registrant’s ordinary shares, as quoted on the Nasdaq Global Market, on June 26, 2019. |
| | |
| 3) | Represents an automatic increase of 1,765,474 Ordinary Shares to the number of shares available for issuance under the 2014 Plan, effective January 1, 2019 as was further approved by the Board of Directors in its meeting held on March 27, 2019. The remainder of ordinary shares available for issuance under the 2014 Plan were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on February 26, 2018 (Registration No. 333-223232), Form S-8 filed with the Securities and Exchange Commission on August 14, 2017 (Registration No. 333- 219969), Form S-8 (Registration No. 333-210583) on April 4, 2016 and Form S-8 filed with the Securities and Exchange Commission on March 3, 2015 (Registration No. 333-202463). |
Explanatory Note
This Registration Statement on Form S-8 registers additional Ordinary Shares under the Registrant’s 2014 Employee Share Ownership and Option Plan (the “2014 Plan”). The aggregate number of Ordinary Shares reserved and available for issuance under the 2014 Plan is subject to an approved mechanism for annual increase each January 1, which began in January 2015, by an amount equal to four percent of the number of Ordinary Shares issued and outstanding on a fully diluted basis on the immediately preceding December 31 or such lesser number of Ordinary Shares as determined by the Administrator (as defined in the Plan). Accordingly, on January 1, 2019, the number of Ordinary Shares reserved and available for issuance under the Plan increased by 1,765,474 as was further approved by our Board of Directors in its meeting held on March 27, 2019. This Registration Statement registers these additional 1,765,474 Ordinary Shares. The additional Ordinary Shares are of the same class as other securities relating to the 2014 Plan for which the Registrant’s registration statement filed on Form S-8 (Registration No. 333-223232) on February 26, 2018, Form S-8 (Registration No. 333-219969) on August 14, 2017, Form S-8 (Registration No. 333-210583) on April 4, 2016 and Form S-8 (Registration No. 333-202463) on March 3, 2015, is effective. The information contained in the Registrant’s registration statement on Form S-8 (Registration No. 333-223232), Form S-8 (Registration No. 333-219969), Form S-8 (Registration No. 333-210583) and Form S-8 (Registration No. 333-202463) is hereby incorporated by reference pursuant to General Instruction E.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits
See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this Registration Statement on Form S-8, which Exhibit Index is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Or Yehuda, Israel, on this 27th day of June, 2019.
| | Vascular Biogenics Ltd. |
| | | |
| | By: | /s/ Dror Harats |
| | | Dror Harats |
| | | Chief Executive Officer |
POWER OF ATTORNEY
We, the undersigned officers and directors of Vascular Biogenics Ltd., hereby severally constitute and appoint Dror Harats and Amos Ron, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign for us and in our names in the capacities indicated below any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated below on this 27th day of June, 2019.
| Signatures | | Title | | Date |
| | | | | |
| /s/ Dror Harats | | Chief Executive Officer and Director | | June 27, 2019 |
| Dror Harats | | (Principal Executive Officer) | | |
| | | | | |
| /s/ Amos Ron | | Chief Financial Officer | | June 27, 2019 |
| Amos Ron | | (Principal Financial Officer and Principal Accounting Officer) | | |
| | | | | |
| /s/ Bennett M. Shapiro | | Non-Executive Director | | June 27, 2019 |
| Bennett M. Shapiro | | | | |
| | | | | |
| /s/ Ruth Arnon | | Non-Executive Director | | June 27, 2019 |
| Ruth Arnon | | | | |
| | | | | |
| /s/ Ruth Alon | | Non-Executive Director | | June 27, 2019 |
| Ruth Alon | | | | |
| | | | | |
| /s/ Shmuel Ben Zvi | | Non-Executive Director | | June 27, 2019 |
| Shmuel Ben Zvi | | | | |
| | | | | |
| /s/ Ron Cohen | | Non-Executive Director | | June 27, 2019 |
| Ron Cohen | | | | |
| | | | | |
| /s/ David Hastings | | Non-Executive Director | | June 27, 2019 |
| David Hastings | | | | |
| | | | | |
| /s/ Susan Kelley | | Non-Executive Director | | June 27, 2019 |
| Susan Kelley | | | | |
| | /s/Donald J. Puglisi | | Authorized Representative in the United States |
| Name: | Donald J. Puglisi | | |
| Title: | Authorized Representative in the United States | | |
EXHIBIT INDEX
| (1) | Filed as Exhibit 3.2 to the Registrant’s Registration Statement on Form F-1 (File No. 333-196584), filed previously with the Commission on June 25, 2014 and incorporated by reference herein. |
| (2) | Filed as Exhibit 3.3 to the Registrant’s Registration Statement on Form F-1 (File No. 333-196584), filed previously with the Commission on June 25, 2014 and incorporated by reference herein. |
| (3) | Filed as Exhibit 3.4 to the Registrant’s Registration Statement on Form F-1 (File No. 333-196584), filed previously with the Commission on June 25, 2014 and incorporated by reference herein. |
| (4) | Filed as Exhibit 10.17 to the Registrant’s Registration Statement on Form F-1 (File No. 333-196584), filed previously with the Commission on June 25, 2014 and incorporated by reference herein. |
